{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:58:08Z","timestamp":1788195488770,"version":"build-2803163510"},"reference-count":21,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2025,1,31]]},"DOI":"10.1536\/ihj.24-306","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T22:11:54Z","timestamp":1737065514000},"page":"21-27","source":"Crossref","is-referenced-by-count":2,"title":["Ticagrelor and the Risk of In-Hospital Gout"],"prefix":"10.1536","volume":"66","author":[{"given":"Hong","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Dali University"},{"name":"Yunnan Trans-plateau Cardiovascular Disease of Prevention and Treatment Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Jiangxue","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Dali University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Dali University"},{"name":"Yunnan Trans-plateau Cardiovascular Disease of Prevention and Treatment Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Dali University"},{"name":"Yunnan Trans-plateau Cardiovascular Disease of Prevention and Treatment Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xitong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Dali University"},{"name":"Yunnan Trans-plateau Cardiovascular Disease of Prevention and Treatment Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Dali University"},{"name":"Yunnan Trans-plateau Cardiovascular Disease of Prevention and Treatment Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Dali University"},{"name":"Yunnan Trans-plateau Cardiovascular Disease of Prevention and Treatment Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Dali University"},{"name":"Yunnan Trans-plateau Cardiovascular Disease of Prevention and Treatment Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-Hua","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The First Affiliated Hospital of Dali University"},{"name":"Yunnan Trans-plateau Cardiovascular Disease of Prevention and Treatment Research Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. VAN Giezen JJ, Nilsson L, Berntsson P, <i>et al<\/i>. Ticagrelor binds to human P2Y (12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Haemost 2009; 7: 1556-65.","DOI":"10.1111\/j.1538-7836.2009.03527.x"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kastrati A. New anti-platelet agents: the end of resistance? Thromb Res 2012; 130 Suppl 1: S53-5.","DOI":"10.1016\/j.thromres.2012.08.275"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y (12) receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 2010; 66: 487-96.","DOI":"10.1007\/s00228-009-0778-5"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Gager GM, Jilma B, Winter MP, <i>et al<\/i>. Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients. Eur J Clin Invest 2020; 50: e13304.","DOI":"10.1111\/eci.13304"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Parker WA, Storey RF. Long-term antiplatelet therapy following myocardial infarction: implications of PEGASUS-TIMI 54. Heart 2016; 102: 783-9.","DOI":"10.1136\/heartjnl-2015-307858"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Granger CB, Berger PB. Understanding the Adverse Effects of Ticagrelor in Practice. JAMA Cardiol 2016; 1: 381-3.","DOI":"10.1001\/jamacardio.2016.1018"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. So A, Thorens B. Uric acid transport and disease. J Clin Invest 2010; 120: 1791-9.","DOI":"10.1172\/JCI42344"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Wallentin L, Becker RC, Budaj A, <i>et al<\/i>. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361: 1045-57.","DOI":"10.1056\/NEJMoa0904327"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Bonaca MP, Bhatt DL, Cohen M, <i>et al<\/i>. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015; 372: 1791-800.","DOI":"10.1056\/NEJMoa1500857"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Drivelegka P, Jacobsson LTH, Lindstr\u00f6m U, Bengtsson K, Dehlin M. Incident Gout and Risk of First-Time Acute Coronary Syndrome: A Prospective, Population-Based Cohort Study in Sweden. Arthritis Care Res (Hoboken) 2023; 75: 1292-9.","DOI":"10.1002\/acr.25018"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Stamp LK, Frampton C, Drake J, Doughty RN, Troughton RW, Richards AM. Associations of Gout and Baseline Serum Urate Level With Cardiovascular Outcomes: Analysis of the Coronary Disease Cohort Study. Arthritis Rheumatol 2019; 71: 1733-8.","DOI":"10.1002\/art.41007"},{"key":"12","unstructured":"12. Huang KH, Tai CJ, Tsai YF, Kuan YH, Lee CY. Correlation between Gout and Coronary Heart Disease in Taiwan: A Nationwide Population-Based Cohort Study. Acta Cardiol Sin 2019; 35: 634-40."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Shiozawa A, Szabo SM, Bolzani A, Cheung A, Choi HK. Serum Uric Acid and the Risk of Incident and Recurrent Gout: A Systematic Review. J Rheumatol 2017; 44: 388-96.","DOI":"10.3899\/jrheum.160452"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Butler K, Teng R. Evaluation and characterization of the effects of ticagrelor on serum and urinary uric acid in healthy volunteers. Clin Pharmacol Ther 2012; 91: 264-71.","DOI":"10.1038\/clpt.2011.223"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Gong M, Wen S, Nguyen T, Wang C, Jin J, Zhou L. Converging Relationships of Obesity and Hyperuricemia with Special Reference to Metabolic Disorders and Plausible Therapeutic Implications. Diabetes Metab Syndr Obes 2020; 13: 943-62.","DOI":"10.2147\/DMSO.S232377"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Larsson SC, Burgess S, Micha\u00eblsson K. Genetic association between adiposity and gout: a Mendelian randomization study. Rheumatology (Oxford) 2018; 57: 2145-8.","DOI":"10.1093\/rheumatology\/key229"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Jung JH, Song GG, Ji JD, <i>et al<\/i>. Metabolic syndrome: prevalence and risk factors in Korean gout patients. Korean J Intern Med 2018; 33: 815-22.","DOI":"10.3904\/kjim.2016.062"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Yu X, Wang T, Huang S, Zeng P. Evaluation of the causal effects of blood lipid levels on gout with summary level GWAS data: two-sample Mendelian randomization and mediation analysis. J Hum Genet 2021; 66: 465-73.","DOI":"10.1038\/s10038-020-00863-0"},{"key":"19","unstructured":"19. Wu Y, Chu C, Song P, Yang Y, Lin C, Xu Q. Plasma D-dimer is a Promising Indicator for the Treatment of Acute Gouty Attack. Ann Clin Lab Sci 2018; 48: 435-9."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Chen S, Huang X, Huang Y, <i>et al<\/i>. Role of plasma fibrinogen in assessing disease activity of patients with gout. Clin Chim Acta 2020; 510: 483-7.","DOI":"10.1016\/j.cca.2020.08.012"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Jee YH, Jung KJ, Park YB, Spiller W, Jee SH. Causal effect of alcohol consumption on hyperuricemia using a Mendelian randomization design. Int J Rheum Dis 2019; 22: 1912-9.","DOI":"10.1111\/1756-185X.13668"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/66\/1\/66_24-306\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T04:18:11Z","timestamp":1738383491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/66\/1\/66_24-306\/_article"}},"subtitle":["A Retrospective Analysis and Nomogram Model Development"],"short-title":[],"issued":{"date-parts":[[2025,1,31]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.24-306","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,31]]},"article-number":"24-306"}}